|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Calcium singnal in the ER, it's role in neuronal placity and neurodegerative disorders显示文摘 | Laferl FM Chan SL | 2000 | Trends Neurosci2000，23，5： | 1 |
| 2 | A randomized, prospective trial of ribavirin 400 rag/day versus 800 mg/day in combination with peg interferon alfa-2a in hepatitis C virus genotypes2 and 3 显示文摘 | Ferenei P Laferl H Scherzer TM | 2008 | Hepatology2008，47，6： | 1 |
| 3 | Randomized comparison of 12 or 24 weeks of peg interferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2 /3 infection 显示文摘 | Ferenci P Brunner H Laferl H | 2008 | Hepatology2008，47，6： | 1 |
| 4 | Acute encephalopathy associated with influenza A virus infection显示文摘 | Steininger C Popow-Kraupp T Laferl H | 2003 | Clin Infect Dis2003，36，5： | 1 |
| 5 | Linking calcium to Abeta and Alzheimer's disease显示文摘 | Green KN Laferlal FM | 2008 | Neuron2008，59，2： | 1 |
| 6 | Prospective study of viral clearance and CD4 + T-cell response in acute hepatitis C primary infection and reinfection显示文摘 | Judith H. Aberle Elisabeth Formann Petra Steindl-Munda Lukas Weseslindtner Calin Gurguta Gabriela Perstinger Evelyn Grilnberger Hermann Laferl Hans P. Dienes Theresia Popow-Kraupp Peter Ferenci Heidemarie Holzmann | 2006 | Journal of Clinical Virology2006，，1： | 1 |
| 7 | Effect of gender and ITPA polymorphisms on ribavirin-induced anemia in chronic hepatitis C patients显示文摘 | Thomas-Matthias Scherzer Albert Friedrich St?ttermayer Rudolf Stauber Andreas Maieron Michael Strasser Hermann Laferl Remy Schwarzer Christian Datz Karoline Rutter Sandra Beinhardt Petra Munda Harald Hofer Peter Ferenci | 2013 | Journal of Hepatology2013，，： | 1 |
| 8 | Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response显示文摘 | FERENCI P LAFERL H SCHERZER T M | 2008 | Gastroenterology2008，135，2： | 1 |
| 9 | Peginterferon alfa-2a/ribavirin for 48 or 72 weeks in hepatitis C genotypes 1 and 4 patients with slow virologic response显示文摘 | Ferenci P Laferl H Scherzer TM | 2010 | Gastroenterology2010，138，2： | 1 |
| 10 | Peginterferon alfa-2a and riba- virin for 24 weeks in hepatitis C type 1 and 4 patients with rapid viro- logical response显示文摘 | Ferenci P Laferl H Scherzer TM | 2008 | Gastroenterology2008，135，2： | 1 |
| 11 | A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3显示文摘 | Ferenci P Laferl H Scherzer TM | 2008 | Hepatology2008，47，6： | 1 |
| 12 | Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection 显示文摘 | Ferenci P Brunner H Laferl H | 2008 | Hepatology2008，47，6： | 1 |
| 13 | Rapid reversible co ma with intravenous gamma hydroxybutyrate in a moxifloxatin treated patient显示文摘 | Koehler G Haimann A Laferl H | 2005 | Clin Drug Investig2005，25，8： | 1 |
| 14 | Serum Level of IP-10 Increases Predictive Value of IL28B Polymorphisms for Spontaneous Clearance of Acute HCV Infection显示文摘 | Sandra Beinhardt Judith H. Aberle Michael Strasser Emina Dulic–Lakovic Andreas Maieron Anna Kreil Karoline Rutter Albert F. Staettermayer Christian Datz Thomas M. Scherzer Robert Strassl Martin Bischof Rudolf Stauber Gerd Bodlaj Hermann Laferl Heidemarie | 2012 | Gastroenterology2012，，1： | 1 |
| 15 | Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response显示文摘 | Ferenci P Laferl H Scherzer TM | 2008 | Gastroenterology2008，135，2： | 1 |
| 16 | Rapid reversible coma with intravenous gamma-hydroxybutyrate in a moxifloxacin-treated patient显示文摘 | Koehler G Haimann A Laferl H | 2005 | Clin Drug Investig2005，25，8： | 1 |
| 17 | 干扰素α-2a加利巴韦林联用或不用金刚烷胺对慢性丙型肝炎病毒基因1型感染者的治疗:一项随机、双盲、安慰剂对照研究显示文摘Background/Aims: Amantadine may augment virological response rates to interferon-based therapy in chronic hepatitis C patients. Using a novel design, amantadine was studied in na ve genotype 1 patients treated in combination with peginterferon alfa-2a (40KD)/ribavirin. Methods: Patients enrolled in this randomized, placeo-controlled multicenter trial were stratified by single-dose interferon sensitivity (stratum I, 24 h HCV-RNA decline >1.4log 10; II, 0.8-1.39log10; III, < 0.8log10; a reliable means of identifying nonresponders to interferon/ribavirin) and fibrosis grade (F0/1/2 vs. F3/4) at baseline. All patients received peginterferon alfa-2a (40KD) 180 μ g/week plus ribavirin 1000-1200 mg/day and were randomized to receive amantadine 100 mg twice daily (N=114) or placebo (N=95) for 48 weeks. Results: Week 24 virological response rates in strata II and III, the primary outcome, were similar in patients treated with amantadine (63.7% ) or placebo (65.7% ), as were sustained virological response rates at week 72 (46.5 and 51.6% , respectively). Adverse event profiles were similar and amantadine did not improve health-related quality of life compared with placebo. Interferon sensitivity was the only significant predictor of treatment outcome. Conclusions: Adding amantadine to peginterferon alfa-2a (40KD)/ribavirin combination therapy does not augment virological response rates in genotype 1 patients. Virological response was almost exclusively determined by interferon sensitivity at baseline. | Ferenci P. Formann E. Laferl H. 刘丽娜 | 2006 | 世界核心医学期刊文摘(胃肠病学分册)2006，2，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员